These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8817300)

  • 1. Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance.
    Donaldson C; Hundley V; McIntosh E
    Health Econ; 1996; 5(3):267-9. PubMed ID: 8817300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency.
    Richardson G; Manca A
    Health Econ; 2004 Dec; 13(12):1203-10. PubMed ID: 15386669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of an intensive group training protocol compared to physiotherapy guideline care for sub-acute and chronic low back pain: design of a randomised controlled trial with an economic evaluation. [ISRCTN45641649].
    van der Roer N; van Tulder MW; Barendse JM; van Mechelen W; Franken WK; Ooms AC; de Vet HC
    BMC Musculoskelet Disord; 2004 Nov; 5():45. PubMed ID: 15560843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
    Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
    Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity and Life After Survival of a Cardiac Arrest (ALASCA) and the effectiveness of an early intervention service: design of a randomised controlled trial.
    Moulaert VR; Verbunt JA; van Heugten CM; Bakx WG; Gorgels AP; Bekkers SC; de Krom MC; Wade DT
    BMC Cardiovasc Disord; 2007 Aug; 7():26. PubMed ID: 17723148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis alongside clinical trials: problems and potential.
    Drummond M
    J Rheumatol; 1995 Jul; 22(7):1403-7. PubMed ID: 7562785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-minimisation analysis versus cost-effectiveness analysis, revisited.
    Dakin H; Wordsworth S
    Health Econ; 2013 Jan; 22(1):22-34. PubMed ID: 22109960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluations alongside equivalence and noninferiority trials.
    Gandjour A
    Value Health; 2009 Jun; 12(4):628; author reply 629. PubMed ID: 19900261
    [No Abstract]   [Full Text] [Related]  

  • 14. Design issues for conducting cost-effectiveness analyses alongside clinical trials.
    Ramsey SD; McIntosh M; Sullivan SD
    Annu Rev Public Health; 2001; 22():129-41. PubMed ID: 11274515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis alongside clinical trials: practical considerations. The Economics Workgroup.
    Drummond M; O'Brien B
    J Rheumatol; 1995 Jul; 22(7):1418-9. PubMed ID: 7562789
    [No Abstract]   [Full Text] [Related]  

  • 16. Methodological developments in randomized controlled trial-based economic evaluations.
    Thorn JC; Noble SM; Hollingworth W
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):843-56. PubMed ID: 25179207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On individual preferences and aggregation in economic evaluation in healthcare.
    Liljas B; Lindgren B
    Pharmacoeconomics; 2001; 19(4):323-35. PubMed ID: 11383750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to read clinical journals: VII. To understand an economic evaluation (part B).
    Can Med Assoc J; 1984 Jun; 130(12):1542-9. PubMed ID: 6428730
    [No Abstract]   [Full Text] [Related]  

  • 19. Health economic evaluations alongside clinical trials: a review of study protocols at the Swedish Medical Products Agency.
    Lindfors A; Feltelius N; Lundkvist J
    Int J Technol Assess Health Care; 2007; 23(3):392-6. PubMed ID: 17579944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raising the standards of trial-based economic evaluation: the devil is in the detail.
    Backhouse ME
    Value Health; 2005; 8(5):519-20. PubMed ID: 16176490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.